Memantine Ratiopharm

Memantine, the active ingredient in Memantine Ratiopharm, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of Alzheimer’s disease in adults.

GNH USA supplies Memantine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease. - Mild to moderate Alzheimer’s disease: may improve cognition and daily functioning when used as adjunct therapy. - Moderate to severe Alzheimer’s disease: helps maintain cognitive abilities and slows functional decline. - Behavioral symptoms in Alzheimer’s disease: may reduce agitation and improve overall patient behavior.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Confusion: temporary disorientation. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic injury: abnormal liver function tests. - Psychosis: hallucinations or delusional thoughts. - Suicidal ideation: thoughts of self‑harm.

Memantine should be used with caution in specific clinical situations. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes regularly. - History of seizures: evaluate risk versus benefit before initiating therapy. - Concomitant NMDA agonists: avoid combined use due to opposing mechanisms. - Pregnancy and lactation: risk unknown; discuss potential benefits and risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism may enhance central effects. - Other NMDA antagonists: combined use can lead to excessive inhibition. Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhancement of hypotensive effect. - CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation. - Diuretics: may alter plasma concentrations of memantine.